Skip to main content
. 2021 Feb 8;49(5):2509–2521. doi: 10.1093/nar/gkab054

Figure 2.

Figure 2.

Validation of fusion transcripts. (A) Venn diagram of identified fusions in three datasets, NB172 (NCI TARGET), Validation-NB (NB-v, 14 neuroblastoma patients plus 8 neuroblastoma cell lines) and adrenal gland (161 samples from normal human adrenal gland). A significant number of fusions detected in NB-v were present in the NB172 cohort, chi-square with Yate's correction P-value <0.001. (B) Enrichment of fusion transcript genes unique to the NB172 and the NB-v cohorts on chromosomal arms 2p and 17q. (C) Venn diagram of identified number of fusions in three datasets, NB172 (NCI TARGET), Rhabdoid (65 Rhabdoid tumor patient samples) and Osteosarcoma (177 Osteosarcoma patient samples). (D) Comparison of the number of neuroblastoma (NB) and osteosarcoma (OS) tumors with at least one fusion transcript containing TP53. (E) Validation of fusion transcripts by RT-PCR in neuroblastoma tumors (NB), juvenile adrenal glands (JAG) and adult adrenal gland (AG). GAPDH was used for normalization. P-values in (A) were calculated by chi-square test with Yate's correction and in (B) by Fisher's exact test. ***P< 0.001.